The first GLP-1 agonist pill for Type 2 diabetes has been approved by the European Medicines Agency (EMA). Rybelsus (known as oral semaglutide in clinical trials) is a once-daily tablet version of Ozempic, a GLP-1 agonist injection, to be taken alone or in combination with other treatments for Type 2 diabetes.
Rybelsus, manufactured by Novo Nordisk, was approved in the US in September 2019. This approval provides more options for people with Type 2 diabetes – data shows that Rybelsus lowers blood glucose and improves heart health, reducing the risk of heart attack, stroke, and heart-related death.
Talk with your diabetes team for more information.